Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): A randomised, controlled, open-label trial

The Lancet Oncology

Volumn 14, Issue 10, 2013, Pages 1020-1026

  Katsumata, Noriyuki ^a   Yasuda, Makoto ^b   Isonishi, Seiji ^b   Takahashi, Fumiaki ^c   Michimae, Hirofumi ^c   Kimura, Eizo ^d   Aoki, Daisuke ^e   Jobo, Toshiko ^f   Kodama, Shoji ^g   Terauchi, Fumitoshi ^h   Sugiyama, Toru ⁱ   Ochiai, Kazunori ^b  

^a NIPPON MEDICAL SCHOOL MUSASHI KOSUGI HOSPITAL   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c KITASATO UNIVERSITY   (Japan)

^d Kousei General Hospital   (Japan)

^e KEIO UNIVERSITY   (Japan)

^f Social Insurance Sagamino Hospital   (Japan)

^g NIIGATA CANCER CENTER HOSPITAL   (Japan)

^h TOKYO MEDICAL UNIVERSITY   (Japan)

ⁱ IWATE MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ADULT; ADVANCED CANCER; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CONTINUOUS INFUSION; CONTROLLED STUDY; DOSE DENSIFICATION; DOSE RESPONSE; DRUG EFFICACY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; JAPAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OVARY CANCER; OVERALL SURVIVAL; PERITONEUM CANCER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; UTERINE TUBE CARCINOMA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DISEASE-FREE SURVIVAL; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PACLITAXEL; PERITONEAL NEOPLASMS; PROPORTIONAL HAZARDS MODELS;

EID: 84882998935     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(13)70363-2     Document Type: Article

References (18)

1. Thigpen T, Dubois A, McAlpine J, et al. First-line therapy in ovarian cancer trials. Int J Gynecol Cancer 2011, 21:756-762.
2. Katsumata N, Yasuda M, Takahashi F, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 2009, 374:1331-1338.
3. Yedema CA, Kenemans P, Wobbes T, et al. Use of serum tumor markers in the differential diagnosis between ovarian and colorectal adenocarcinomas. Tumour Biol 1992, 13:18-26.
4. Jelliffe RW Letter: creatinine clearance: bedside estimate. Ann Intern Med 1973, 79:604-605.
5. Rustin GJ, Timmers P, Nelstrop A, et al. Comparison of CA-125 and standard definitions of progression of ovarian cancer in the intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide. J Clin Oncol 2006, 24:45-51.
6. Bookman MA, Brady MF, McGuire WP, et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol 2009, 27:1419-1425.
7. Jaaback K, Johnson N, Lawrie TA Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev 2011, 11. CD005340.
8. Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011, 365:2473-2483.
9. duPont NC, Brady MF, Burger RA, et al. Prognostic significance of ethnicity and age in advanced stage ovarian cancer: an analysis of GOG 218. SGO Annual Meeting. 2013; abstract 54.
10. Fuh K, Shin J, Blansit K, et al. The treatment and survival differences of Asians versus whites with epithelial ovarian cancer. SGO Annual Meeting. 2013; abstract 53.
11. Kurman RJ, Shih IeM The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 2010, 34:433-443.
12. Anglesio MS, George J, Kulbe H, et al. IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer. Clin Cancer Res 2011, 17:2538-2548.
13. Behbakht K, Sill MW, Darcy KM, et al. Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study. Gynecol Oncol 2011, 123:19-26.
14. du Bois A, Luck HJ, Meier W, et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003, 95:1320-1329.
15. Ando M, Minami H, Ando Y, et al. Multi-institutional validation study of carboplatin dosing formula using adjusted serum creatinine level. Clin Cancer Res 2000, 6:4733-4738.
16. Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006, 145:247-254.
17. Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009, 53:982-992.
18. Pignata S, Scambia G, Lauria R, et al. A randomized multicenter phase III study comparing weekly versus every 3 weeks carboplatin (C) plus paclitaxel (P) in patients with advanced ovarian cancer (AOC): Multicenter Italian Trials in Ovarian Cancer (MITO-7)-European Network of Gynaecological Oncological Trial Groups (ENGOT-ov-10) and Gynecologic Cancer Intergroup (GCIG) trial. Proc Am Soc Clin Oncol 2013, 31(suppl). abstr LBA5501.